Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merrimack Pharmaceuticals
Biotech
Elevation raises $65M to run tumor-agnostic phase 2
Elevation Oncology has raised $65 million to complete enrollment in a registration-enabling phase 2 cancer trial of an ex-Merrimack drug.
Nick Paul Taylor
Nov 18, 2020 8:35am
Synlogic hires ex-Alnylam VP to lead medical department
Sep 5, 2019 8:05am
Former Merrimack CEO becomes new Yumanity chief—Chutes & Ladders
Jul 12, 2019 9:30am
After exiting troubled Merrimack, ex-CEO becomes new chief at Yumanity
Jul 10, 2019 9:07am
Merrimack's CEO, CFO and president abandon ship—Chutes & Ladders
Jul 3, 2019 9:30am
After canning clinical pipeline, Merrimack CEO, CFO abandon ship
Jul 2, 2019 10:18am
